Evotec Q3 Revenue Hits €164.9M as EBITDA Loss Narrows 89%, Reaffirms 2026 Guidance
EVO sits 18% above its 52-week low of $1.33.
Summary
Evotec's Q3 revenue came in at €164.9M, essentially flat year over year, but adjusted EBITDA improved to -€1.6M from -€15.0M, an 89.1% swing driven by lower cost of revenue. The nine-month picture is weaker: revenue fell 13.1% to €465.0M and adjusted EBITDA deteriorated to -€44.3M from -€16.9M, largely on the prior-year Sandoz license sale and delayed JEB programs. Management reaffirmed FY2026 guidance of €570-610M revenue and -€105 to -€70M adjusted EBITDA, and laid out a 2030 framework of roughly €1B revenue with a 20% adjusted EBITDA margin by year-end 2028. The Horizon restructuring is running ahead of plan, with more than 20% of the €75M annual savings target already delivered and about half of planned workforce cuts done. This follows the October 14 preliminary 9M release that already flagged revenue above expectations, and the October 15 Mubadala block-trade exit that removed a large holder. The Vertex selection of Just-Evotec Biologics for commercial povetacicept manufacturing is the standout commercial win. Watch the 8 a.m. EST analyst call today for detail on the ongoing strategic review and JEB commercial ramp.
At the time of this announcement, EVO was trading at $1.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $568.6M. The 52-week trading range was $1.33 to $4.09. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.